Leppänen, J., Bogdanoff, S., Lehenkari, P. P., Saarnio, J., Kauppila, J. H., Karttunen, T. J., … Helminen, O. (2017). Tenascin-C and fibronectin in normal esophageal mucosa, Barrett’s esophagus, dysplasia and adenocarcinoma. Oncotarget, 8(40). https://doi.org/10.18632/oncotarget.19196
Tenascin-C and fibronectin in normal esophageal mucosa, Barrett's esophagus, dysplasia and adenocarcinoma
|Author:||Leppänen, Joni1; Bogdanoff, Sara1; Lehenkari, Petri P.1;|
1Cancer and Translational Medicine Research Unit, Medical Research Center Oulu, University of Oulu and Oulu University Hospital, Oulu, Finland
2Department of Molecular Medicine and Surgery, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
|Online Access:||PDF Full Text (PDF, 5.7 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2019081223876
|Publish Date:|| 2019-08-12
Background: Tenascin-C and fibronectin are adhesive glycoproteins modulating the structure of the extracellular matrix and cellular functions. Their expression and function in esophageal adenocarcinoma is poorly known. The aim of this study was to evaluate the expression of tenascin-C and fibronectin in esophageal adenocarcinoma and its precursor stages.
Results: Stromal tenascin-C and fibronectin expression were found in all evaluated lesion types. Expression of both molecules increased from gastric metaplasia towards adenocarcinoma (p<0.05). In carcinomas, tenascin-C expression in the bulk was associated with T-stage (p=0.006), presence of lymph node (p=0.004) and distant organ metastases (p=0.007). Abundant tenascin-C expression associated with poor survival (p=0.034) in univariate analysis. Fibronectin expression associated to T-stage (p=0.030). Expression of tenascin-C or fibronectin in the tumor invasive front was not associated to clinicopathological variables or survival. No significant correlation with tumor/stroma percentage, cancer-associated fibroblasts or mean vascular density was observed with either tenascin-C or fibronectin.
Methods: Tenascin-C and fibronectin were stained immunohistochemically and assessed in esophageal specimens from patients with esophageal adenocarcinoma (n=90) or dysplasia (n=30). Structures and lesion were evaluated including normal esophagus (n=77), gastric (n=61) or intestinal (n=51) metaplasia without dysplasia, and low-grade (n=42) or high-grade (n=34) dysplasia, and esophageal adenocarcinoma (n=90). In carcinomas, both bulk and invasive front were separately evaluated. In addition, tumor/stroma percentage, cancer-associated fibroblasts and mean vascular density were evaluated.
Conclusions: Tenascin-C and fibronectin are upregulated in esophageal adenocarcinoma when compared to Barrett’s esophagus and dysplasia. Increased tenascin-C expression is associated with metastasis and poor prognosis in esophageal adenocarcinoma.
|Pages:||66865 - 66877|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
This work was supported by grants from the Orion Research Foundation (J.H.K.), Thelma Mäkikyrö Foundation (J.H.K., H.H), Päivikki and Sakari Sohlberg Foundation (H.H.), Georg C. and Mary Ehrnroot Foundation (J.H.K., H.H.), Sigrid Juselius Foundation (J.H.K.), the Finnish Medical Foundation (H.H) and Eemil Aaltonen Foundation (H.H, J.L).
© Leppänen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.